Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk.
Epidemiology
Longitudinal
Prevention
Visual acuity
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
20
07
2021
pubmed:
1
11
2021
medline:
6
4
2022
entrez:
31
10
2021
Statut:
ppublish
Résumé
Visual impairment has emerged as a potential modifiable risk factor for dementia. However, there is a lack of large studies with objective measures of vision and with more than 10 years of follow-up. We investigated whether visual impairment is associated with an increased risk of incident dementia in UK Biobank and European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk). In both cohorts, visual acuity was measured using a "logarithm of the minimum angle of resolution" (LogMAR) chart and categorized as no (≤0.30 LogMAR), mild (>0.3 to ≤0.50 LogMAR), and moderate to severe (>0.50 LogMAR) impairment. Dementia was ascertained through linkage to electronic medical records. After restricting to those aged ≥60 years, without prevalent dementia and with eye measures available, the analytic samples consisted of 62 206 UK Biobank and 7 337 EPIC-Norfolk participants, respectively. In UK Biobank and EPIC-Norfolk, respectively, 1 113 and 517 participants developed dementia over 11 and 15 years of follow-up. Using multivariable Cox proportional-hazards models, the hazard ratios for mild and moderate to severe visual impairment were 1.26 (95% confidence interval [CI]: 0.92-1.72) and 2.16 (95% CI: 1.37-3.40), in UK Biobank, and 1.05 (95% CI: 0.72-1.53) and 1.93 (95% CI: 1.05-3.56) in EPIC-Norfolk, compared to no visual impairment. When excluding participants censored within 5 years of follow-up or with prevalent poor or fair self-reported health, the direction of the associations remained similar for moderate impairment but was not statistically significant. Our findings suggest visual impairment might be a promising target for dementia prevention; however, the possibility of reverse causation cannot be excluded.
Identifiants
pubmed: 34718565
pii: 6412742
doi: 10.1093/gerona/glab325
pmc: PMC8974347
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-704Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C864/A14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : UKRI Future Leaders Fellowship
Organisme : Medical Research Council
ID : MR/T040912/1
Pays : United Kingdom
Organisme : Nicolaus and Margrit Langbehn Foundation
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America.
Références
BMJ. 2020 Feb 12;368:m131
pubmed: 32051121
Br J Cancer. 1999 Jul;80 Suppl 1:95-103
pubmed: 10466767
Alzheimers Dement. 2018 Aug;14(8):1038-1051
pubmed: 29621480
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2162-2168
pubmed: 32043518
BMJ. 2017 Jun 22;357:j2709
pubmed: 28642251
J Am Med Dir Assoc. 2017 May 1;18(5):388-395
pubmed: 28043804
BMJ Open. 2019 Feb 21;9(2):e025077
pubmed: 30796124
Int J Epidemiol. 2014 Aug;43(4):1063-72
pubmed: 23771720
Curr Neuropharmacol. 2018;16(7):971-977
pubmed: 29210654
Psychol Aging. 1994 Sep;9(3):339-55
pubmed: 7999320
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
BMJ Open. 2013 Mar 19;3(3):
pubmed: 23516272
J Am Geriatr Soc. 2004 Dec;52(12):1996-2002
pubmed: 15571533
Nat Rev Neurol. 2019 Jan;15(1):11-24
pubmed: 30532084
Health Qual Life Outcomes. 2019 Feb 1;17(1):24
pubmed: 30709406
Br J Ophthalmol. 2021 Sep 13;:
pubmed: 34518160
Qual Life Res. 2018 Aug;27(8):1957-1971
pubmed: 29404924
Alzheimers Dement. 2015 Jan;11(1):70-98
pubmed: 25022540
J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):890-896
pubmed: 30452551
Eur J Epidemiol. 2019 Jun;34(6):557-565
pubmed: 30806901
Eur J Epidemiol. 2019 Feb;34(2):141-152
pubmed: 30610413
Lancet Glob Health. 2021 Feb;9(2):e130-e143
pubmed: 33275950
Eye (Lond). 2018 Aug;32(8):1296-1303
pubmed: 29610523
Neurosci Biobehav Rev. 2016 Oct;69:166-73
pubmed: 27484869
Emerg Themes Epidemiol. 2016 Oct 28;13:11
pubmed: 27800007
Alzheimers Dement. 2018 Feb;14(2):178-186
pubmed: 28943197
J Alzheimers Dis. 2021;83(3):1073-1087
pubmed: 34397414
JAMA Ophthalmol. 2020 Jun 1;138(6):624-633
pubmed: 32297918
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Lancet. 2014 Mar 1;383(9919):828-40
pubmed: 23927914
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2010 Mar 15;171(6):728-35
pubmed: 20150357
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Ophthalmology. 2021 Aug;128(8):1135-1149
pubmed: 33422559
Psychol Aging. 1997 Mar;12(1):12-21
pubmed: 9100264
Ageing Res Rev. 2015 Sep;23(Pt B):154-66
pubmed: 26123097
Sci Rep. 2020 Jun 4;10(1):9109
pubmed: 32499618
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Int J Epidemiol. 2018 Feb 1;47(1):226-235
pubmed: 29040562
Sci Rep. 2019 Dec 23;9(1):19660
pubmed: 31873079
J Am Geriatr Soc. 2017 Sep;65(9):2074-2081
pubmed: 28734053
Alzheimers Dement (Amst). 2020 Jul 07;12(1):e12054
pubmed: 32671180
Sci Rep. 2018 Feb 1;8(1):2083
pubmed: 29391510
Psychogeriatrics. 2020 May;20(3):262-270
pubmed: 31799771
Lancet Glob Health. 2017 Sep;5(9):e888-e897
pubmed: 28779882
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248